Table 3.
N = 13 | Treatment‐emergent, treatment‐related adverse events | |
---|---|---|
All grades n (%) | Grade 3 n (%) | |
Any adverse event | 9 (69.2) | 1 (7.7)a |
Dysgeusia | 9 (69.2) | 0 |
Muscle spasms | 5 (38.5) | 0 |
Alopecia | 4 (30.8) | 0 |
Decreased appetite | 4 (30.8) | 0 |
Blood creatinine phosphokinase increased | 3 (23.1) | 0 |
Constipation | 3 (23.1) | 0 |
Diarrhea | 3 (23.1) | 0 |
No grade 4 or 5 treatment‐related adverse events were reported in this study.
One patient experienced grade 3 treatment‐related pyrexia.